Abstract: A water dispersible granular composition comprising: at least one solid agrochemically active substance; at least one sorptive filler; at least one first agrochemically acceptable excipient; at least one liquid or low melting agrochemically active substance; and, at least one second agrochemically acceptable excipient. The invention further relates to a process of preparing the water dispersible granular composition.
Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
September 22, 2020
Assignee:
Vifor Fresenius Medical Care Renal Pharma Ltd.
Abstract: A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a triptan compound to a subject.
Abstract: The present application relates to sunscreen formulations, including foamable sunscreen formulations, that comprise zinc oxide and titanium dioxide particles, suitably in the size range of about 1-100 nm. The compositions suitably produce a minimal residual whitening effect when applied to a skin surface.
Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
November 19, 2019
Assignee:
ENDORECHERCHE, INC.
Inventors:
Mohamed El-Alfy, Fernand Labrie, Louise Berger
Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
Type:
Grant
Filed:
July 5, 2017
Date of Patent:
November 19, 2019
Assignee:
NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
Abstract: The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.
Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
Type:
Grant
Filed:
March 26, 2015
Date of Patent:
October 1, 2019
Assignee:
MILLENNIUM PHARMACEUTICALS, INC.
Inventors:
Rachael L. Brake, Viviana Bozon, Ching-Kuo J. Chow, James C. Dinunzio, Katherine M. Galvin, Karuppiah Kannan, Yuki Kodono, Qunli Xu
Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
September 24, 2019
Assignee:
RHINONASE, INC.
Inventors:
Kambiz Yadidi, Amanda Quiroga, Jagdeep Shur, Jeffrey B. Harris
Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
Abstract: Disclosed are methods of making oral pharmaceutical compositions that contain substantially crush resistant drug containing microparticles. The microparticles may contain an active pharmaceutical agent, a polymer and a plasticizer. The microparticles may be un-coated (so as to impart an immediate release profile) or coated so as to impart an extended release (ER), delayed release (DR) or delayed extended release (DER) profile. One or more of the populations of microparticles may be coated with a taste masking composition. The methods may produce oral compositions such as orally disintegrating tablets that contain one or more these types of microparticles in order to further customize the release profile. Also disclosed are the oral compositions, per se, and methods of using same for their intended purposes.
Type:
Grant
Filed:
March 24, 2015
Date of Patent:
September 10, 2019
Assignee:
Kashiv BioSciences, LLC
Inventors:
Siva Ram Kiran Vaka, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah, Kanji Meghpara
Abstract: The invention is a method of treating osteoarthritis or normalizing a condition of osteoarthritis comprising administering to an animal or a human in need thereof a therapeutically effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof.
Abstract: The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.
Type:
Grant
Filed:
April 3, 2014
Date of Patent:
August 6, 2019
Assignee:
EVOTEC INTERNATIONAL GMBH
Inventors:
John Alan Kemp, Ian Michael Hunneyball, Timothy Tasker
Abstract: Methods of preparation and pharmaceutical uses of pyrazolopyrimidone derivatives are described. Specifically, methods of preparation and pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
Abstract: Aerosol compositions, comprising a) at least one propellant and b) at least one cosmetic preparation, including (i) at least one strengthening active substance and (ii) at least one alkoxylated carboxylic acid ester of the following formula (I), in which R1 represents a straight-chain or branched, saturated or unsaturated alkyl group having 6 to 24 carbon atoms, R2 represents hydrogen or an alkyl group having 1 to 4 carbon atoms, R3 and R4 represent, independently of each other, hydrogen or an alkyl group having 1 to 4 carbon atoms, R5 represents a straight-chain or branched, saturated or unsaturated alkyl group having 6 to 24 carbon atoms or a phenyl group, and n and m represent, independently of each other, the numbers 0 or 1 to 20, are suitable for the application of hair cosmetic agents in the form of spray mists, quickly collapsing foams.
Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro [cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.
Type:
Grant
Filed:
September 22, 2016
Date of Patent:
June 25, 2019
Assignee:
GRUENENTHAL GMBH
Inventors:
Stefanie Frosch, Klaus Linz, Thomas Christoph
Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Abstract: The invention refers to a drippable ophthalmic gel, said gel having composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of >0.2% by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10% by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.